{"id":"W2703678370","doi":"10.1200/jco.2016.34.15_suppl.101","title":"A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Atezolizumab; Medicine; Agonist; Internal medicine; Antibody; Pharmacokinetics; Immunotherapy; Adverse effect; Oncology; Pharmacology; Cancer; Pembrolizumab; Immunology; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001689587,0.001333213,0.001852079,0.0004752788,0.0003523424,0.001087923,0.0008552778,0.001071875,0.002510359],"category_scores_gemma":[0.0009528828,0.0007693039,0.001421397,0.0004349538,0.0008951707,0.0008764538,0.000423293,0.003434797,0.0008733415],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001188388,"about_ca_system_score_gemma":0.001400172,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00077078,"about_ca_topic_score_gemma":0.001586051,"domain_scores_codex":[0.9994047,0.0002607173,0.00003572517,0.0001151205,0.00005758675,0.0001261959],"domain_scores_gemma":[0.9992672,0.0001108767,0.0001580052,0.00009805574,0.00004548891,0.0003203878],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6082636,0.126341,0.01460465,0.0008027251,0.00143831,0.0005299775,0.000823141,0.005892835,0.08974235,0.0004025839,0.003401981,0.1477569],"study_design_scores_gemma":[0.2860806,0.6893774,0.01434183,0.00002608364,0.0003493266,0.0004606474,0.00008439583,0.001417051,0.00452106,0.0001737162,0.003139137,0.00002874229],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938083,0.001189262,0.0006307547,0.0002511295,0.00007737542,0.002121345,0.0005863745,0.00008021393,0.001255231],"genre_scores_gemma":[0.9926052,0.000833263,0.001685977,0.0004205526,0.00008048033,0.001622347,0.001164685,0.00002617051,0.001561368],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002510359,"threshold_uncertainty_score":0.008935452,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03716742583024048,"score_gpt":0.4133332806145038,"score_spread":0.3761658547842633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}